On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure

摘要

BackgroundTrials of iron chelator regimens have increased the treatment options for cardiac siderosis in beta-thalassemia major (TM) patients. Treatment effects with improved left ventricular (LV) ejection fraction (EF) have been observed in patients without overt heart failure, but it is unclear whether these changes are clinically meaningful.